triple glp-1/gip/glucagon receptor agonist LY3437943, a novel glucagon, GIP, and GLP-1 for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism Upcoming wave of hormone-based therapies

Significant Limitations : High costs, access barriers, tolerability issues, and sustainability concerns prevent these agents from achieving their full transformative potential at a population level

A simple journal can help your clinician

GLP-1 receptor agonists and GLP-1/GIP combination therapies have become foundational treatments for type 2 diabetes and obesity

The oral segment is projected to witness the fastest CAGR from 2025 to 2032, driven by the growing demand for needle-free alternatives and the launch of oral GLP-1 receptor agonists such as Rybelsus (oral semaglutide) and future pipeline products such as orforglipron